CRISPR THERAPEUTICS AG (CRSP) Stock Price, Quote, News and Overview
NASDAQ:CRSP - Nasdaq - CH0334081137 - Common Stock - Currency: USD
CRSP Quote, Performance and Key Statistics
47.91
-2.52 (-5%)
The current stock price of CRSP is 47.91 USD. In the past month the price increased by 8.32%. In the past year, price decreased by -42.96%.
CRSP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About CRSP
Company Profile
CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug and currently employs 407 full-time employees. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
Company Info
CRISPR THERAPEUTICS AG
Baarerstrasse 14
Zug ZUG CH-6300 CH
CEO: Samarth Kulkarni
Employees: 407
Company Website: https://crisprtx.com/
Investor Relations: http://ir.crisprtx.com/
Phone: 41415613279
CRISPR THERAPEUTICS AG / CRSP FAQ
What is the stock price of CRISPR THERAPEUTICS AG today?
The current stock price of CRSP is 47.91 USD. The price decreased by -5% in the last trading session.
What is the ticker symbol for CRISPR THERAPEUTICS AG stock?
The exchange symbol of CRISPR THERAPEUTICS AG is CRSP and it is listed on the Nasdaq exchange.
On which exchange is CRSP stock listed?
CRSP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CRISPR THERAPEUTICS AG stock?
34 analysts have analysed CRSP and the average price target is 81.73 USD. This implies a price increase of 70.6% is expected in the next year compared to the current price of 47.91. Check the CRISPR THERAPEUTICS AG stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CRISPR THERAPEUTICS AG worth?
CRISPR THERAPEUTICS AG (CRSP) has a market capitalization of 4.11B USD. This makes CRSP a Mid Cap stock.
How many employees does CRISPR THERAPEUTICS AG have?
CRISPR THERAPEUTICS AG (CRSP) currently has 407 employees.
What are the support and resistance levels for CRISPR THERAPEUTICS AG (CRSP) stock?
CRISPR THERAPEUTICS AG (CRSP) has a support level at 38.65 and a resistance level at 49.09. Check the full technical report for a detailed analysis of CRSP support and resistance levels.
Is CRISPR THERAPEUTICS AG (CRSP) expected to grow?
The Revenue of CRISPR THERAPEUTICS AG (CRSP) is expected to grow by 297.49% in the next year. Check the estimates tab for more information on the CRSP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CRISPR THERAPEUTICS AG (CRSP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CRSP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CRSP, evaluating the profitability, health, valuation and growth aspects
- CRISPR THERAPEUTICS AG (CRSP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CRISPR THERAPEUTICS AG (CRSP) Sales and EPS estimates to see what analysts future expectations are.
- CRISPR THERAPEUTICS AG (CRSP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CRISPR THERAPEUTICS AG (CRSP) Insider and Institutional Ownership to learn about the owners and their transactions.
- CRISPR THERAPEUTICS AG (CRSP) Stock Chart to make your own analysis
- CRISPR THERAPEUTICS AG (CRSP) Latest news and press-releases to stay up to date.
Does CRISPR THERAPEUTICS AG (CRSP) stock pay dividends?
CRSP does not pay a dividend.
When does CRISPR THERAPEUTICS AG (CRSP) report earnings?
CRISPR THERAPEUTICS AG (CRSP) will report earnings on 2025-05-06, before the market open.
What is the Price/Earnings (PE) ratio of CRISPR THERAPEUTICS AG (CRSP)?
CRISPR THERAPEUTICS AG (CRSP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.37).
What is the Short Interest ratio of CRISPR THERAPEUTICS AG (CRSP) stock?
The outstanding short interest for CRISPR THERAPEUTICS AG (CRSP) is 23.12% of its float. Check the ownership tab for more information on the CRSP short interest.
CRSP Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to CRSP. When comparing the yearly performance of all stocks, CRSP is a bad performer in the overall market: 85.95% of all stocks are doing better.
CRSP Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CRSP. While CRSP has a great health rating, there are worries on its profitability.
CRSP Financial Highlights
Over the last trailing twelve months CRSP reported a non-GAAP Earnings per Share(EPS) of -4.37. The EPS decreased by -122.96% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.34% | ||
| ROE | -18.96% | ||
| Debt/Equity | 0 |
CRSP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to CRSP. The Buy consensus is the average rating of analysts ratings from 34 analysts.
For the next year, analysts expect an EPS growth of -13.85% and a revenue growth 297.49% for CRSP